"Mifepristone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.
| Descriptor ID |
D015735
|
| MeSH Number(s) |
D04.210.500.365.415.580
|
| Concept/Terms |
R-38486- R-38486
- R 38486
- RU-486
- RU 486
- RU486
- R38486
- RU-38486
- RU 38486
- RU38486
|
Below are MeSH descriptors whose meaning is more general than "Mifepristone".
Below are MeSH descriptors whose meaning is more specific than "Mifepristone".
This graph shows the total number of publications written about "Mifepristone" by people in this website by year, and whether "Mifepristone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mifepristone" by people in Profiles.
-
Exploring Consumer Preferences for Pharmacy Provision of Mifepristone in the Human-centered Design Discovery Phase. Womens Health Issues. 2024 Nov-Dec; 34(6):580-588.
-
Pharmacists' experiences dispensing misoprostol and readiness to dispense mifepristone. J Am Pharm Assoc (2003). 2024 Jan-Feb; 64(1):245-252.e1.
-
ExPAND Mifepristone: Medical Management of Miscarriage and Abortion in FQHCs. Ann Fam Med. 2023 Sep-Oct; 21(5):468.
-
Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review. Contraception. 2022 11; 115:62-66.
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
-
Mifepristone restrictions and primary care: Breaking the cycle of stigma through a learning collaborative model in the United States. Contraception. 2021 07; 104(1):24-28.
-
Expanding access to medication abortion through pharmacy dispensing of mifepristone: Primary care perspectives from Illinois. Contraception. 2021 07; 104(1):98-103.
-
Contraceptive Provision after Medication and Surgical Abortion. Womens Health Issues. 2017 Sep - Oct; 27(5):546-550.
-
Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol. 2016 Feb; 30(2):158-72.
-
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.